Christine Stabell Benn and Peter Aaby

“whether the prevention [of the disease] comes at a prohibitive price”

Christine Stabell Benn and Peter Aaby · said date not stated · reported 2026-11-05

In a joint statement, Benn and Aaby clarified they were testing whether preventing hepatitis B comes at a prohibitive cost such as death or other negative health outcomes.

“unique window of opportunity”

Christine Stabell Benn and Peter Aaby · said date not stated · reported 2026-11-05

The researchers argued that the period before Guinea-Bissau begins at-birth hepatitis B vaccination in 2028 provides an opportunity to compare outcomes between babies vaccinated at birth and those vaccinated at six weeks.